STOCK TITAN

Bio Rad Labs Inc - BIO STOCK NEWS

Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.

Bio-Rad Laboratories, Inc. (BIO) delivers essential innovations in clinical diagnostics and life science research through its global operations. This dedicated news hub provides investors and industry professionals with timely access to official announcements, financial updates, and scientific advancements.

Discover comprehensive collection of press releases covering quarterly earnings, regulatory milestones, product launches, and strategic partnerships. Our curated feed ensures transparent access to BIO's operational developments across its dual focus areas: laboratory-quality diagnostic systems and cutting-edge research tools.

Key updates include innovations in digital PCR technology, quality control solutions for clinical testing, and advancements supporting biopharmaceutical development. Bookmark this page for direct access to primary-source information affecting BIO's market position and research impact.

Rhea-AI Summary

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, has announced its participation in Wells Fargo's 2024 Healthcare Conference. CEO Norman Schwartz and CFO Roop K. Lakkaraju will engage in a fireside chat on Wednesday, September 4, at 2:15 PM Eastern Time (11:15 AM Pacific Time).

The event will be accessible via live webcast and a replay will be available afterwards. Interested parties can find both the live stream and replay in the Investor Relations section of Bio-Rad's website at bio-rad.com. This participation underscores Bio-Rad's commitment to engaging with investors and sharing insights about the company's operations and future prospects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
conferences
-
Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO and BIO.B) has announced the appointment of Jon DiVincenzo as President and Chief Operating Officer, effective September 9, 2024. DiVincenzo, who brings over 30 years of industry experience, will replace the retiring Andy Last. He joins Bio-Rad from Labcorp Holdings Inc., where he most recently served as Executive Vice President and President of Central Laboratories and International.

DiVincenzo's extensive background includes leadership roles at PerkinElmer, Enzymatics, and EMD Millipore. His experience spans strategic, operational, and commercial organizations in both life science and clinical diagnostics. Norman Schwartz, Bio-Rad's Chairman and CEO, expressed enthusiasm about DiVincenzo's appointment, highlighting his track record in operations, marketing, and product development as integral to the company's future success.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
management
-
Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO and BIO.B) reported Q2 2024 financial results with total net sales of $638.5 million, a 6.3% decrease from Q2 2023. The Life Science segment saw a 16.5% decrease, while Clinical Diagnostics increased by 2.1%. Gross margin improved to 55.6% from 53.2% in Q2 2023. The company reported a net loss of $2,165.5 million, primarily due to changes in the fair market value of its Sartorius AG investment. Non-GAAP net income was $88.5 million, or $3.11 per diluted share. Bio-Rad updated its 2024 outlook, expecting a 2.5-4.0% revenue decline and a non-GAAP operating margin of 12.0-13.0%. The board authorized an additional $500 million for share repurchases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
Rhea-AI Summary

Bio-Rad Laboratories (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced it will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, after market close. The company will host a conference call at 2 PM Pacific Time (5 PM Eastern Time) on the same day to discuss the results. Investors can participate by dialing 800-343-4849 (U.S.) or 203-518-9856 (outside U.S.) with the access code: BIORAD. A live webcast will be available on the company's website, and a replay will be accessible for up to a year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.77%
Tags
conferences earnings
-
Rhea-AI Summary

Bio-Rad Laboratories has appointed Anette Engelhardt as Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024. Engelhardt joins from Cepheid, where she was a Senior Vice President and General Manager. At Cepheid, she managed emerging growth opportunities and led global R&D, strategy, and product management. She has significant experience in the diagnostics field, having held senior roles at bioMerieux and served as CEO of AB BIODISK. Andy Last, Bio-Rad’s Executive VP and COO, expressed confidence in Engelhardt's ability to drive the company's clinical diagnostics strategy and product development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
Rhea-AI Summary

Bio-Rad Laboratories, a leader in life science research and clinical diagnostics, announced that CEO Norman Schwartz and CFO Roop K. Lakkaraju will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 6, 2024, at 10:30 AM ET (7:30 AM PT). A live webcast and replay will be accessible via the Investor Relations section of Bio-Rad’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
Rhea-AI Summary

Bio-Rad Laboratories, Inc. reported first-quarter 2024 financial results with total net sales of $610.8 million, a decrease of 9.8% compared to the same period in 2023. While Life Science segment sales dropped by 25.3%, Clinical Diagnostics segment sales increased by 4.7%. Net income for the quarter was $383.9 million, or $13.45 per share, compared to $69.0 million, or $2.32 per share, in 2023. Bio-Rad remains cautiously optimistic about a gradual biopharma market recovery and confident in their long-term strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
-
Rhea-AI Summary

Bio-Rad Laboratories, Inc. will have its COO and CFO participate in a fireside chat during the RBC Capital Markets Global Healthcare Conference on May 14, 2024. The event will be webcasted and available for replay on the company's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
conferences
-
Rhea-AI Summary

Bio-Rad Laboratories, Inc. announced the promotion of James J. Barry to Executive Vice President and President of the Life Science Group, succeeding Dr. Simon May. Barry's extensive experience and leadership roles in quality systems and global manufacturing make him well-suited for the position. The CEO expressed confidence in Barry's ability to lead the global life science business, acknowledging May's contributions to the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
management
Rhea-AI Summary
Bio-Rad Laboratories, Inc. (NYSE: BIO) will report its first quarter 2024 financial results on May 7, 2024. The conference call will take place at 2 PM Pacific Time. Investors can access the call through dial-in or a live webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
conferences earnings
Bio Rad Labs Inc

NYSE:BIO

BIO Rankings

BIO Stock Data

6.67B
19.44M
15.56%
84.59%
3.08%
Medical Devices
Laboratory Analytical Instruments
Link
United States
HERCULES